Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events
in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear …

Type 2 diabetes and atherosclerosis have gradually garnered great attention as
inflammatory diseases. Previously, the fact that Interleukin-1β (IL-1β) accelerates the …

Purpose We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the
deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice.(2) The …

Background/Aims. NLRP3 inflammasome, an inflammasome which consists of nucleotide‐
binding oligomerization domain‐(Nod‐) like receptor3 (NLRP3) scaffold, apoptosis …

Diabetic cardiomyopathy (DCM), a common consequence of longstanding diabetes mellitus,
is initiated by death of cardiomyocyte. Hyperglycemia-induced reactive oxygen species …

The aim of this study was to evaluate the effects of chronic treatment with empagliflozin, a
potent and selective sodium glucose cotransporter-2 inhibitor, in a murine model of diet …

Background NLRP3 inflammasome can be activated by high glucose and links inflammation
and metabolic disease. This study aimed to investigate the role of NLRP3 inflammasome in …

The Nod-like receptor 3 (NLRP3) inflammasome is an intracellular sensor that sets off the
innate immune system in response to microbial-derived and endogenous metabolic danger …

Bacground Sodium–glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4
inhibitors (DPP4I) are used to treat type 2 diabetes (T2DM). DPP4 inhibitors (DPP4) …

Type 2 diabetes mellitus (T2DM), accounting for 90–95% cases of diabetes, is characterized
by chronic inflammation. The mechanisms that control inflammation activation in T2DM are …